These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 30362966)

  • 1. Andexanet Alfa for Reversing Factor Xa Inhibition.
    Sible AM; Nawarskas JJ
    Cardiol Rev; 2019; 27(2):108-111. PubMed ID: 30362966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Andexanet alfa for reversal of factor Xa inhibitors: a critical review of the evidence.
    Abdulrehman J; Eikelboom JW; Siegal DM
    Future Cardiol; 2019 Nov; 15(6):395-404. PubMed ID: 31668083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Andexanet alfa: a recombinant mimetic of human factor Xa for the reversal of anticoagulant therapies.
    Escolar G; Diaz-Ricart M; Arellano-Rodrigo E
    Drugs Today (Barc); 2017 May; 53(5):271-282. PubMed ID: 28650000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Andexanet Alfa: First Global Approval.
    Heo YA
    Drugs; 2018 Jul; 78(10):1049-1055. PubMed ID: 29926311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Andexanet alfa (ONDEXXYA
    Yajima T; Higashimori M; Takata C; Sasabe T
    Nihon Yakurigaku Zasshi; 2023; 158(1):89-100. PubMed ID: 36596498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Specific antidotes against direct oral anticoagulants: A comprehensive review of clinical trials data.
    Tummala R; Kavtaradze A; Gupta A; Ghosh RK
    Int J Cardiol; 2016 Jul; 214():292-8. PubMed ID: 27082776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity.
    Siegal DM; Curnutte JT; Connolly SJ; Lu G; Conley PB; Wiens BL; Mathur VS; Castillo J; Bronson MD; Leeds JM; Mar FA; Gold A; Crowther MA
    N Engl J Med; 2015 Dec; 373(25):2413-24. PubMed ID: 26559317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Andexanet alfa for the reversal of factor Xa inhibitors.
    Favresse J; Hardy M; van Dievoet MA; Sennesael AL; Douxfils J; Samama CM; Vornicu O; Dincq AS; Lessire S; Mullier F
    Expert Opin Biol Ther; 2019 May; 19(5):387-397. PubMed ID: 30974977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Andexanet alfa for the reversal of anticoagulant activity in patients treated with direct and indirect factor Xa inhibitors.
    Nafee T; Aslam A; Chi G; Pahlavani S; Nimri D; Kuchkuntla AR; Talib U; Michalak N; Daaboul Y; Korjian S; Gallo A; Gibson CM
    Expert Rev Cardiovasc Ther; 2017 Apr; 15(4):237-245. PubMed ID: 28282497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A New Option for Reversing the Anticoagulant Effect of Factor Xa Inhibitors: Andexanet Alfa (ANDEXXA).
    Rogers KC; Finks SW
    Am J Med; 2019 Jan; 132(1):38-41. PubMed ID: 30053385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors.
    Milling TJ; Middeldorp S; Xu L; Koch B; Demchuk A; Eikelboom JW; Verhamme P; Cohen AT; Beyer-Westendorf J; Gibson CM; Lopez-Sendon J; Crowther M; Shoamanesh A; Coppens M; Schmidt J; Albaladejo P; Connolly SJ;
    Circulation; 2023 Mar; 147(13):1026-1038. PubMed ID: 36802876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recommendations for the use of andexanet alfa in the management of bleeding in patients on oral factor Xa inhibitors in Switzerland: Guideline from the Working Party Hemostasis of the Swiss Society of Hematology.
    Angelillo-Scherrer A; Casini A; Studt JD; Gerber B; Alberio LA; Fontana P
    Swiss Med Wkly; 2023 Jul; 153():40113. PubMed ID: 37499160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How can we reverse bleeding in patients on direct oral anticoagulants?
    Crowther M; Cuker A
    Kardiol Pol; 2019; 77(1):3-11. PubMed ID: 30338501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Andexanet Alfa (Andexxa) Formulary Review.
    Beik N; Reddy P; Sylvester KW; Connell NT; Giugliano RP; Piazza G; Connors JM
    Crit Pathw Cardiol; 2019 Jun; 18(2):66-71. PubMed ID: 31094731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct oral anticoagulants: a review on the current role and scope of reversal agents.
    Chaudhary R; Sharma T; Garg J; Sukhi A; Bliden K; Tantry U; Turagam M; Lakkireddy D; Gurbel P
    J Thromb Thrombolysis; 2020 Feb; 49(2):271-286. PubMed ID: 31512202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apixaban and rivaroxaban anti-Xa level utilization for guidance of administration of andexanet alfa: a case series.
    Morton C; Lista A; Jakowenko N; Salazar E; Donahue KR
    J Thromb Thrombolysis; 2022 Jan; 53(1):235-239. PubMed ID: 34236614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors.
    Connolly SJ; Milling TJ; Eikelboom JW; Gibson CM; Curnutte JT; Gold A; Bronson MD; Lu G; Conley PB; Verhamme P; Schmidt J; Middeldorp S; Cohen AT; Beyer-Westendorf J; Albaladejo P; Lopez-Sendon J; Goodman S; Leeds J; Wiens BL; Siegal DM; Zotova E; Meeks B; Nakamya J; Lim WT; Crowther M;
    N Engl J Med; 2016 Sep; 375(12):1131-41. PubMed ID: 27573206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retrospective review of Andexanet Alfa versus 4-Factor Prothrombin Complex Concentrate for reversal of DOAC-Associated Intracranial Hemorrhage.
    Troyer C; Nguyen W; Xie A; Wimer D
    J Thromb Thrombolysis; 2023 Jan; 55(1):149-155. PubMed ID: 36355324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Andexanet alfa in the treatment of acute major bleeding related to apixaban and rivaroxaban: a profile of its use in the USA.
    Heo YA
    Drugs Ther Perspect; 2018; 34(11):507-512. PubMed ID: 30459509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What is the role of andexanet alfa in the reversal of anticoagulant effects?
    Sewell JH; Williams L; McKnight E; Nguyen A; Sarac M
    JAAPA; 2021 Jan; 34(1):8-9. PubMed ID: 33332828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.